Allergy Protection Articles & Analysis
5 news found
About Bentrio™ Bentrio™ (AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. ...
(NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus Pharma Ltd., Dubai ("Avernus") in the United Arab Emirates, ...
(NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio™ has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that country. ...
(NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on its development activities in RNA therapeutics. ...
Key market and technology drivers include concern over barrier protection, latex allergies, ease of use, tactility and comfort. Glove manufacturers are finding new opportunities and more shelf-space to fill in the blossoming economies of Latin America and Asia which are implementing stricter infection control standards. Awareness of hygiene requirements for ...